Glenmark Pharma Ltd Quarterly Results Q1 FY26

Glenmark Pharmaceuticals Ltd., a prominent name in India’s pharmaceutical industry, has released its Q1 FY26 (April–June 2025) results. This update offers a snapshot of the company’s revenue trends, profitability, dividend policy, and future strategy. Whether you’re a stakeholder or simply tracking the pharma sector, these figures help provide clarity on Glenmark’s recent performance and outlook.

Below is a refined breakdown of Glenmark Pharma’s Q1 FY26 results and what they might mean going forward.

Glenmark Pharma Q1 FY26 financial performance

In Q1 FY26, Glenmark Pharma reported consolidated revenue of ₹3,264.44 crore, a modest increase of 0.6% year-on-year (versus ₹3,244.19 crore in Q1 FY25). Outlook Business+2Business Standard+2

However, net profit experienced a sharp decline: the company posted ₹46.97 crore in consolidated profit after tax, which is down about 86% YoY from ₹340.24 crore in Q1 FY25. Outlook Business+2Business Standard+2

EBITDA for the quarter stood at ₹580 crore, reflecting a slight 1.3% contraction year-on-year, and an EBITDA margin of around 17.8%. ETPharma.com+2Outlook Business+2

These results were impacted by a substantial provision for a legal settlement in the U.S., which we discuss below in more detail.

Segment- and region-wise performance

• The domestic (India) business saw revenue of approximately ₹1,239.9 crore, up ~3.7% YoY. scanx.trade+3Outlook Business+3ETPharma.com+3
• Emerging markets revenue was ~₹572.1 crore, showing a marginal increase of ~0.2%. Business Standard+1
• The North America business brought in ~₹778 crore, down ~0.3% YoY, although it achieved sequential growth of ~8.9%. Business Standard+2ETPharma.com+2
• Europe revenues were ~₹667.8 crore, down about 4% YoY from ₹695.7 crore. Business Standard+1

The decline in profitability is largely attributed to a ₹323.23 crore provision (approximately USD 37.75 million) to settle U.S. antitrust litigation. This exceptional item was charged to profit and loss. scanx.trade+3Outlook Business+3Business Standard+3

Excluding that exceptional item, the underlying profit before tax would have been stronger, though still under pressure. Business Standard+1

This performance suggests that while revenues held up mildly, margin pressures and non-operating items significantly weighed on the bottom line.

Glenmark Pharma did not declare a dividend in Q1 FY26. (No public disclosure or announcement of an interim dividend was found in company reports or media coverage.)

Given the sharp earnings drop and increased uncertainty, retaining cash for operations and contingencies might be a prudent move. Nonetheless, the company has historically aimed to maintain a consistent dividend policy in healthier years.

Following the results, Glenmark Pharma’s stock saw a slight uptick of ~0.6% on the day of announcement, closing at around ₹2,043.95 on the BSE. Business Standard+2ETPharma.com+2

Market reaction was mixed: the revenue stability was viewed as positive, but the sharp profit decline and the litigation-related provision introduced caution. Several analysts highlighted the company’s innovation deal (with AbbVie for its spin-off ISB 2001) as a potentially significant future catalyst. The Economic Times+6Outlook Business+6Business Standard+6

Investor sentiment remains cautiously optimistic: many believe that the fundamentals, especially in domestic and emerging markets, still offer upside if headwinds ease.

Glenmark continues to emphasize expansion in its branded, specialty, and innovative product lines across geographic markets. In particular:

• The company has expressed confidence in achieving double-digit growth in Europe and emerging markets from Q2 FY26 onward. scanx.trade+2ETPharma.com+2
• A major strategic development is the global licensing of ISB 2001 (its cancer trispecific candidate) to AbbVie, for which upfront and milestone considerations could be transformative. The deal is viewed by many analysts as validation of Glenmark’s R&D and innovation capabilities. The Economic Times+5ETPharma.com+5Outlook Business+5
• The company is also investing in process efficiencies, cost optimization, and scaling of markets where it sees immediate traction.

If execution is strong, these levers could help reverse margin pressure and drive more consistent growth in future quarters.

This table highlights the scale of compression in profitability despite relatively stable revenues.

Glenmark Pharma’s Q1 FY26 results point to a challenging quarter: revenue growth remained tepid, and profitability was severely hit by a litigation-related provision. However, the fundamentals in certain geographies (notably India and emerging markets) held up modestly, and the company’s strategic forays into innovation and global licensing may offer upside potential.

For stakeholders, the key watchpoints going forward include:

• Execution on the ISB 2001 licensing and associated milestones
• Ability to regain margin strength post the exceptional item
• Growth momentum in Europe, North America, and emerging markets
• Management of legal, regulatory, and operational headwinds